- Methodology article
- Open Access
Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells
© Cribbs et al.; licensee BioMed Central Ltd. 2013
- Received: 1 October 2013
- Accepted: 7 November 2013
- Published: 12 November 2013
Lentiviral vectors have emerged as efficient vehicles for transgene delivery in both dividing and non-dividing cells. A number of different modifications in vector design have increased biosafety and transgene expression. However, despite these advances, the transduction of primary human T cells is still challenging and methods to achieve efficient gene transfer are often expensive and time-consuming.
Here we present a simple optimised protocol for the generation and transduction of lentivirus in primary human CD45RA+ T cells. We show that generation of high-titre lentivirus with improved primary T cell transduction is dependent upon optimised ultracentrifuge speed during viral concentration. Moreover, we demonstrate that transduction efficiency can be increased with simple modifications to the culturing conditions. Overall, a transduction efficiency of up to 89% in primary human CD45RA+ cells is achievable when these modifications are used in conjunction.
The optimised protocol described here is easy to implement and should facilitate the production of high-titre lentivirus with superior transduction efficiency in primary human T cells without the need for further purification methods.
- Primary lymphocytes
Replication-deficient pseudotyped lentiviral vectors are widely used as basic tools in research and have the potential to be utilised as therapeutic agents in severe immunodeficiencies [1, 2]. Production of HIV-derived lentiviral vectors is performed by transfecting vectors harbouring self-inactivating long terminal repeat (LTR) regions together with the transgene on one vector (the transfer vector), while the additional transcripts required for packaging (Gag/Pro/Pol) and encapsulation (Env) are encoded on separate vectors . In second-generation packaging systems, all packaging genes are encoded by one vector that is transfected along with the transfer vector and encapsulation vector to generate virions. In the third-generation packaging system the Rev gene is encoded on a separate packaging plasmid, leading to increased biosafety .
Concentration of lentiviral stocks is performed to increase lentivirus titre and remove impurities for superior transduction of target cells. Typically ultracentrifugation is used, although other techniques such as ultrafiltration [5–7] and ultracentrifugation over a density gradient [7, 8] are also commonly used. Numerous studies have developed optimised lentiviral production protocols based on these procedures [6, 9, 10], however most approaches have focused their attention on obtaining high lentivirus titre, with little regard given to the infectivity of virus produced.
Efficient lentiviral transduction of numerous cell lines has been demonstrated previously . In contrast, primary human T cells are refractory to transduction by lentivirus, with quiescent T cells being particularly problematic to transduce [12, 13]. Furthermore, the completion of reverse transcription and integration into the genome does not occur unless T cells are activated through the TCR and/or by proliferative cytokines .
In this study we have generated high-titre lentivirus with superior transduction efficiency in primary human T cells. Specifically, we demonstrate that time consuming and costly additional purification methods are dispensable when lentivirus is concentrated using lower centrifuge speeds. This resulted in both increased lentiviral titres and increased infectivity in human primary T cells. Moreover, we show that transduction efficiency can be improved further when optimal conditions are used to culture primary T cells.
HEK 293T/17 cells (ATCC No. CRL-11268) were cultured in high glucose-containing Dulbecco’s modified Eagle’s medium (DMEM; Lonza) supplemented with 10% foetal calf serum (FCS, Gibco) at 37°C at 5% CO2, unless otherwise stated. Human T lymphocyte derived Jurkat cells (ATCC No. TIB-152) were cultured in RPMI 1640 (Lonza) supplemented with 5% FCS prior to transduction.
Primary CD45RA T cell isolation and stimulation
Human peripheral blood mononuclear cells (PBMCs) were isolated from electrophoresis cones (North London Blood Transfusion Service) or healthy volunteers by Ficoll-Hypaque centrifugation. Human blood collections were taken following written informed consent and approval of the London Riverside research committee, REC number: 07/H0706/81 and in agreement with the Helsinki Declaration. Peripheral blood lymphocytes (PBLs) were isolated by centrifugal elutriation. CD4+CD45RA+ cells were isolated from PBLs by negative bead isolation (Miltenyi). Lymphocytes were stimulated with either plate bound anti-CD3 (OKT3 – Insight Biotechnology) and soluble anti-CD28 (BD Pharmingen) or anti-CD3/CD28 activation beads (Invitrogen). Cells were cultured in X-VIVO 15 (Lonza) and supplemented with either 5% FCS or 5% Human serum (Biosera), together with IL-2 (100 ng/mL) and IL-7 (15 ng/mL).
The pCCL-Empty plasmid was constructed from a previously characterised vector, MA1, in which two transgenes can be efficiently transcribed from a bi-directional origin: with the minimal cytomegalovirus promoter for ΔNGFR (a truncated form of the nerve growth factor receptor), and a second transgene transcribed from the human phosphoglycerate kinase promoter . The pCCL-Empty plasmid was kindly provided by Prof M Levings . The lentivirus packaging plasmids, psPAX2, pRSV-Rev, pMDLg/pRRE and the pMD2. G envelope plasmid containing VSV-G were kindly provided by D. Trono . For lentivirus production, plasmids were prepared using the Endofree Plasmid Maxi kit (Qiagen) according to manufacturer’s protocol.
Preparation of flasks for lentivirus production
Lentiviral vectors expressing the ΔNGFR gene were produced as follows. 24 hrs prior to transfection, 25 × 106 293T cells were plated onto poly-L-lysine (Sigma) coated 175 cm2 flasks. Two hrs prior to transfection, medium was replaced with RPMI 1640 supplemented with 5% FCS. All solutions were sterilised by filtration through 0.22 μm filters. Solutions were stored in aliquots at -20°C, and thawed prior to use.
Standard lentivirus production and concentration procedure
The lentiviral transfer vector DNA, together with psPAX2 packaging and pMD2. G envelope plasmid DNA were combined at a ratio of 4:3:1, respectively. Production of 3rd generation lentivirus was performed using the combined ratio of transfer plasmid, packaging plasmid, Env plasmid and pRSV-Rev plasmid at 4:2:1:1, respectively. The precipitate was formed by adding 80 μg of DNA to a final volume of 1.35 mL distilled H2O and 150 μl 2.5M CaCl2 (Sigma). A sterile 2 mL pipette was used to vigorously bubble air through the DNA mix, during which, 1.5 mL 2× HEPES-buffered saline (280 mM NaCl, 50 mM HEPES, 1.5 mM Na2HPO4, pH 7.0) was added dropwise into the precipitate. The solution was briefly vortexed and incubated at room temperature for 30 min. Following this, the solution was mixed again by gentle vortexing, and then added dropwise to the cells. Flasks were rocked gently in a circular motion to distribute the precipitates, and then returned to the incubator at 3% CO2 unless otherwise stated. Four to six hrs later, cells were gently washed once with PBS and fresh growth medium added. Sixteen hrs post-transfection, the medium was replaced with RPMI supplemented with 5% FCS unless otherwise stated and incubated at 5% CO2 for 24 hrs prior to the initial collection of viral supernatant. A second collection was made after a further 24 hrs. The conditioned medium from the two harvests was combined and cleared by centrifugation at 1500 rpm for 5 min at 4°C then passed through a 0.45 μm pore PVDF Millex-HV filter (Millipore).
Concentration of lentivirus using ultracentrifugation was performed with a Sorval Discovery 100 SE centrifuge using an AH-629 rotor. 30 mL of filtered lentivirus supernatant was added to 36 mL pollyallomer conical tubes (Beckman). Centrifugation was performed for 90 min at 90,000 g unless otherwise stated. Supernatant was completely removed and virus pellets resuspended in 300 μL PBS overnight at 4°C and stored at -80°C until use.
Lentiviral transduction of primary T cells
Lentivirus was added to primary CD45RA+ lymphocytes cultured in X-VIVO media supplemented with 10% FCS (initial culturing conditions) or 10% HS (final optimal culturing conditions) and 6 μg/mL polybrene. Lentivirus was then added to give a multiplicity of infection (MOI) of 50. After overnight incubation, lentivirus was removed and fresh media added. Following 48 hrs (initial culturing conditions) or 24 hrs (final optimal culturing conditions) of culture the cells were removed and NGFR+ cells were determined by flow cytometry using antibody APC-CD271 (BD Pharmingen).
Where lipofectamine (Invitrogen) reagents were used for comparison of transfection methods, 80 μg plasmid DNA was again used in the same ratio as with the calcium phosphate method and transfections were carried out according to the manufacturer’s protocol.
Purification of lentivirus using a Mustang Q Acrodisc (PALL) was performed according to the manufacturer’s recommendations. Briefly, 50 mL aliquots of lentivirus supernatant were adjusted to 25 mM Tris-HCl, pH 8.9 and loaded onto a Mustang Q Acrodisc and filtered through the Acrodisc syringe filter. The Acrodisc was eluted using a step gradient ranging from 0.3 to 1.5 M NaCl in 25 mM Tris-HCl, pH 8.5. Filtered supernatant was then added to 36 mL pollyallomer conical tubes and ultracentrifuged at 20,000 g for 90 min.
For concentration using Optiprep (Axis-shield), a 220 μL cushion of Optiprep was added to pollyallomer conical tubes and lentivirus-containing supernatant (30 mL) was gently layered into each tube taking care not to disturb the Optiprep. Samples were ultracentrifuged at 20,000 g for 90 min. Media above the media/Optiprep interface was carefully removed from each tube and discarded. The residual media containing lentivirus and Opitiprep was shaken at 200 rpm for 2 hrs in sealed tubes. The resulting mixture was pooled and centrifuged at 20,000 g for 24 hrs. Supernatant was discarded and the remaining pellet was resuspended in 300 μL of PBS, shaken overnight at 4°C, and then stored at -80°C until use.
Titres were determined by transducing 1 × 105 Jurkat cells in 100 μl of RPMI 1640 growth medium. Titres were determined in triplicate with serial dilutions from 1:10 to 1:1000 for un-concentrated vector stocks, or from 1:100 to 1:10000 for concentrated vector stocks in a final volume of 100 μl with 6 μg/mL polybrene (Sigma). The following day, plates were spun at 1,500 rpm for 5 min to remove cells from suspension and fresh growth medium added. After a further 48 hr incubation, cells were harvested and NGFR expression was determined by flow cytometry using APC-CD271 antibody (BD Pharmingen). Titres were determined based on the percentage of NGFR positive cells and calculated according to the following formula (F × N × D × 1,000)/V, where F = percentage cells positive for NGFR, N = number of cells at time of transduction (usually 1 × 105 cells), D = fold dilution of vector used in transduction, V = volume (μl) of diluted vector sample in each well. The virus titre is expressed as transducing units/mL (TU/mL) ± standard error .
Final simplified production and concentration of lentivirus
25 × 106 293T cells were plated onto poly-L-lysine (Sigma) coated 175 cm2 flasks. Two hrs prior to transfection, medium was replaced with RPMI 1640 supplemented with 5% FCS.
The lentiviral transfer vector DNA, together with packaging and envelope plasmid DNA were combined at a ratio of 4:1:3 respectively. The precipitate was formed by adding 80 μg of DNA to a final volume of 1.35 mL distilled H2O and 150 μl 2.5M CaCl2 (Sigma). A sterile 2 mL pipette was used to bubble air through the DNA mix, during which, 1.5 mL 2x HEPES-buffered saline (280 mM NaCl, 50 mM HEPES, 1.5 mM Na2HPO4, pH 7.0) was added dropwise into the precipitate. The solution was briefly vortexed and incubated at room temperature for 30 min. Following this, the solution was mixed again by gentle vortexing, and then added dropwise to the cells. Flasks were rocked gently in a circular motion to distribute the precipitates, and then returned to the incubator at 3% CO2 unless otherwise stated. Four to six hrs later, cells were gently washed once with PBS and fresh growth medium added. Sixteen hrs post-transfection, the medium was replaced with RPMI supplemented with 5% FCS unless otherwise stated and incubated at 5% CO2 for 24 hrs prior to the initial collection. Sodium butyrate (Sigma) was added 16 hr post-transfection into the culture medium at a final concentration of 1 mM. A second collection was made after a further 24 hrs. The conditioned medium from the two harvests was combined and cleared by centrifugation at 1500 rpm for 5 min at 4°C then passed through a 0.45 μm pore PVDF Millex-HV filter (Millipore).
Concentration of lentivirus using ultracentrifugation was performed with a Sorval Discovery 100 SE centrifuge using an AH-629 rotor. 30 mL of filtered virus supernatant was added to 36 mL pollyallomer conical tubes (Beckman). Centrifugation was performed for 90 min at 20,000 g. Supernatant was completely removed and virus pellets resuspended in 300 μL PBS overnight at 4°C and stored at -80°C until use.
We used Graph Pad Prism 6 for analysis. We used one-way analysis of variance with Bonferroni correction and Student’s t test to determine differences between groups. The results presented are mean ± s.d. P < 0.05 was considered statistically significant.
Comparison of lipofectamine and calcium phosphate transfection to generate lentivirus
In the previous experiments, use of sodium butyrate enhanced the titres of lentiviral vectors in all cases . To determine the optimal concentration of sodium butyrate in the culture medium with the calcium phosphate transfection, lentiviral vector titres produced from cells cultured in medium containing a range of sodium butyrate concentrations were determined. As shown in Figure 1B, compared to non-supplemented transfections, the use of sodium butyrate increased virus titres when present at concentrations of 10 mM down to 1 μM in the culture medium. The highest viral titres were achieved using sodium butyrate at a concentration of 1 mM, with the presence of sodium butyrate at this concentration resulting in a ~6-fold increase in lentiviral titres compared to no sodium butyrate. Therefore for all further experiments 1 mM sodium butyrate was added at 16 hr post-transfection.
Comparison of the second and third lentivirus packaging systems
Comparison of lentivirus titre/transduction efficiency following ultracentrifugation and purification using Optiprep and Acrodisc
Concentrating lentivirus with reduced centrifuge speeds has previously been shown to increase the titre of lentivirus ; however whether this equates to increased transduction efficiency in primary T cells has never been demonstrated. Concentration of lentivirus is usually performed at 90,000 g [5, 23], although some have shown that recovery of virus increases if the virus is centrifuged at a reduced speed of 20,000 g . Similarly we showed a significant increase in virus titre (Figure 3C) and virus recovery (Additional file 1: Figure S1), which correlated with a significant increase in transduction in CD45RA+ T cells when virus was spun at 20,000 g (Figure 3D), suggesting that reduced spin speed improves virion stability and infectivity. Reduction of spin speed to 6,400 g resulted in a substantially reduced lentivirus titre and did not improve transduction of CD45RA+ T cells. These results suggest that optimisation of centrifugation speed is important to generate the highest titre of lentivirus with optimal infectivity and that high spin speeds may reduce virus recovery and lower transduction efficiency in primary human CD45RA+ T cells.
Having determined that concentrating virus at a lower speed results in improved lentivirus titres and transduction efficiency, we next determined whether we could improve lentivirus infectivity further by density gradient concentration (Optiprep) or ultrafiltration (Mustang Q Acrodisc). However, we found that using either Optiprep or Acrodisc concentration techniques resulted in a reduction in overall lentivirus titre (Figure 3E) and virus recovery (Additional file 1: Figure S2), which correlated with reduced transduction of primary CD45RA+ T cells (Figure 3F). These results suggest that centrifuging lentivirus at lower speeds negates the use of more costly and time-consuming purification techniques and is sufficient to remove impurities that may otherwise reduce transduction efficiency.
Achieving high transduction of primary naïve T cells through modification of culturing conditions
Having shown that transduction efficiency can be improved by using CD3/28 activation beads in combination with HS, we next determined transduction efficiency in unstimulated T cells and following 0, 24 and 48 hrs of TCR stimulation. There were no significant changes in the numbers of NGFR expressing cells between CD45RA+ cells that were transduced unstimulated or following stimulation with activation beads for 0, 24 or 48 hrs (Figure 4C). However a significant increase in the MFI of ΔNGFR was seen following transduction after 24 hrs of TCR stimulation (Figure 4D), suggesting that the cell cycle stage at which cells are transduced may be important for increased transgene expression, which is likely due to increased number of transgene integrations per cell.
High transduction efficiency in primary T cells
Lentiviral transduction of exogenous genes into primary cells is technically challenging, requiring the preparation of high titre viral stocks and optimal culture conditions. The generation of lentivirus requires the transfection of a stable producer cell line, such as 293T cells. We have shown that transfection of 293T cells with a second-generation lentivirus system produces virus with sufficiently high titre to transduce primary T cells, compared to the third-generation system. While this approach increased viral titre, the viral supernatants did not generate sufficiently high transduction efficiency. To increase the virus transduction efficiency we sought to concentrate the virus supernatant, thereby allowing for the use of a high MOI whilst at the same time reducing contaminating material in the supernatant. We determined that it was possible to increase virus transduction efficiency by concentration using ultracentrifugation. Transduction efficacy could be improved further by reducing the centrifugal speed from the standard protocol (90,000 g) to 20,000 g. In contrast, Acrodisc and Optiprep concentration and purification techniques gave little improvement over ultracentrifugation, and actually led to reduced viral titres and transduction of primary CD45RA+ T cells, potentially due to an increase in damaged virion particles. In addition to virus generation we also showed that transduction efficiency can be improved by modifications to cell culture conditions, specifically we showed that the strength of TCR stimulation and the time of transduction following stimulation affects transduction efficiency. Interestingly, we also showed that lentivirus can transduce unstimulated T cells to similar efficiency to stimulated primary T cells; however the expression of the transgene is low. Overall, we demonstrate an easy and robust protocol to generate and transduce lentivirus at high efficiency in primary T cells. This robust method is simple to achieve and does not require additional expensive laboratory equipment.
We thank Prof. M. Levings for the pCCL vector; Prof D. Trono for the pMD2. G and psPAX vectors. This work was supported by the Kennedy Trust for Rheumatology Research.
- Young LS, Searle PF, Onion D, Mautner V: Viral gene therapy strategies: from basic science to clinical application. J Pathol. 2006, 208 (2): 299-318. 10.1002/path.1896.View ArticleGoogle Scholar
- Biffi A, Naldini L: Gene therapy of storage disorders by retroviral and lentiviral vectors. Hum Gene Ther. 2005, 16 (10): 1133-1142. 10.1089/hum.2005.16.1133.View ArticleGoogle Scholar
- Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996, 272 (5259): 263-267. 10.1126/science.272.5259.263.View ArticleGoogle Scholar
- Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L: A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998, 72 (11): 8463-8471.Google Scholar
- Kutner RH, Zhang XY, Reiser J: Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc. 2009, 4 (4): 495-505. 10.1038/nprot.2009.22.View ArticleGoogle Scholar
- Sena-Esteves M, Tebbets JC, Steffens S, Crombleholme T, Flake AW: Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol Methods. 2004, 122 (2): 131-139. 10.1016/j.jviromet.2004.08.017.View ArticleGoogle Scholar
- Reiser J: Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther. 2000, 7 (11): 910-913. 10.1038/sj.gt.3301188.View ArticleGoogle Scholar
- Baekelandt V, Eggermont K, Michiels M, Nuttin B, Debyser Z: Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene Ther. 2003, 10 (23): 1933-1940. 10.1038/sj.gt.3302094.View ArticleGoogle Scholar
- al Yacoub N, Romanowska M, Haritonova N, Foerster J: Optimized production and concentration of lentiviral vectors containing large inserts. J Gene Med. 2007, 9 (7): 579-584. 10.1002/jgm.1052.View ArticleGoogle Scholar
- Zhang B, Xia HQ, Cleghorn G, Gobe G, West M, Wei MQ: A highly efficient and consistent method for harvesting large volumes of high-titre lentiviral vectors. Gene therapy. 2001, 8 (22): 1745-1751. 10.1038/sj.gt.3301587.View ArticleGoogle Scholar
- Swainson L, Mongellaz C, Adjali O, Vicente R, Taylor N: Lentiviral transduction of immune cells. Methods Mol Biol. 2008, 415: 301-320.Google Scholar
- Verhoeyen E, Costa C, Cosset FL: Lentiviral vector gene transfer into human T cells. Methods Mol Biol. 2009, 506: 97-114. 10.1007/978-1-59745-409-4_8.View ArticleGoogle Scholar
- Zack JA, Kim SG, Vatakis DN: HIV restriction in quiescent CD4(+) T cells. Retrovirology. 2013, 10: 37-10.1186/1742-4690-10-37.View ArticleGoogle Scholar
- Korin YD, Zack JA: Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol. 1998, 72 (4): 3161-3168.Google Scholar
- Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L: Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol. 2005, 23 (1): 108-116. 10.1038/nbt1049.View ArticleGoogle Scholar
- Allan SE, Alstad AN, Merindol N, Crellin NK, Amendola M, Bacchetta R, Naldini L, Roncarolo MG, Soudeyns H, Levings MK: Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Therapy. 2008, 16 (1): 194-202. 10.1038/sj.mt.6300341.View ArticleGoogle Scholar
- Gorman CM, Howard BH, Reeves R: Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 1983, 11 (21): 7631-7648. 10.1093/nar/11.21.7631.View ArticleGoogle Scholar
- Sakoda T, Kasahara N, Hamamori Y, Kedes L: A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. J Mol Cell Cardiol. 1999, 31 (11): 2037-2047. 10.1006/jmcc.1999.1035.View ArticleGoogle Scholar
- Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L, et al: Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA. 1999, 96 (6): 2988-2993. 10.1073/pnas.96.6.2988.View ArticleGoogle Scholar
- Levin MC, Lidberg U, Jirholt P, Adiels M, Wramstedt A, Gustafsson K, Greaves DR, Li S, Fazio S, Linton MF, et al: Evaluation of macrophage-specific promoters using lentiviral delivery in mice. Gene Ther. 2012, 19 (11): 1041-1047. 10.1038/gt.2011.195.View ArticleGoogle Scholar
- Siwko SK, Bu W, Gutierrez C, Lewis B, Jechlinger M, Schaffhausen B, Li Y: Lentivirus-mediated oncogene introduction into mammary cells in vivo induces tumors. Neoplasia. 2008, 10 (7): 653-662. 651 p following 662View ArticleGoogle Scholar
- Ichim CV, Wells RA: Generation of high-titer viral preparations by concentration using successive rounds of ultracentrifugation. J Transl Med. 2011, 9: 137-10.1186/1479-5876-9-137.View ArticleGoogle Scholar
- Al Yacoub N, Romanowska M, Truss M, Haritonova N, Foerster J: A widely applicable optimized protocol for lentivirus production and virus concentration. Exp Dermatol. 2007, 16 (3): 286-286.Google Scholar
- Maurice M, Verhoeyen E, Salmon P, Trono D, Russell SJ, Cosset FL: Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood. 2002, 99 (7): 2342-2350. 10.1182/blood.V99.7.2342.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.